Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Zevra’s Miplyffa Wins First-Ever US Approval, But In Combination With Off-Label Miglustat
Drug’s List Price Is $1m Per Year On Average
Sep 23 2024
•
By
Mandy Jackson
Zevra will pull the lever on its Miplyffa launch in eight to 12 weeks • Source: Shutterstock
More from New Products
More from Scrip